Controlled substances charge: Court summons Ramdev, Amazon founder

Hisar: The court of chief judicial magistrate Gitanjaali Goel in Ambala has issued summons to 14 people, including yoga guru Baba Ramdev, Acharya Balkrishna, and Amazon founder and executive chairman Jeffrey Preston Bezos, in a case alleging the use of controlled substances under the NDPS Act in Patanjali’s Divya Pharmacy product Bala Churna. All accused have been directed to appear before the court on April 13.

The summons were issued prior to the court taking cognisance of the complaint, which also alleges that the product was sold online through Amazon using a fabricated supplementary trust deed.

The complaint was filed on Nov 5, 2024, by Deepak Sandhu, an athlete from Ambala’s Dayal Bagh area. Sandhu named Divya Pharmacy, Haridwar; its trustees Baba Ramdev and Acharya Balkrishna; Patanjali Ayurved Limited; Amazon; Jeffrey Bezos; senior vice-president Amit Agarwal; and senior officials of the ministry of AYUSH and Uttarakhand AYUSH department as accused.

Those summoned include AYUSH secretary Rajesh Kotecha, joint adviser Debashish Panda, Kaustuba Upadhyay, Uttarakhand AYUSH licensing authority officer GCS Jangpangi, licensing officer Mithlesh Kumar, director Arun Kumar Tripathi, and Drug Controller General of India Rajiv Raghuvanshi.

The case invokes provisions of the Bharatiya Nyaya Sanhita, the NDPS Act, the Information Technology Act, the Drugs and Cosmetics Act, and the Drugs Rules.

Sandhu alleged that his health deteriorated after consuming ‘Bala Churna’, which he purchased through Amazon in 2019. He claimed subsequent inquiries and a test report from the Central govt’s drugs dept confirmed the presence of controlled substances — ephedrine and pseudoephedrine — constituting an offence under Section 9A of the NDPS Act.

The complaint also states that the product violated Rule 161 of the Drugs Rules, 1945, by failing to disclose ingredients, prompting a later notice from the Uttarakhand AYUSH department.

Sandhu further alleged that Divya Pharmacy issued a fraudulent supplementary trust deed in 2024 to facilitate product sales. He said he obtained prior sanction from the Ministry of AYUSH under Section 218 of BNSS to proceed against officials.

Related Posts

Sun Pharma Launches UNLOXCYT for Advanced Skin Cancer in US

New Delhi: Sun Pharmaceutical Industries Limited has announced that UNLOXCYT (cosibelimab-ipdl) is now available in the United States for prescription by healthcare professionals for the treatment of adults with metastatic…

Unlicensed medical device stock worth Rs. 4.47 lakh seized in Gurugram raid

In a significant crackdown on the illegal sale of medical equipment, a team of drug control officers in Haryana conducted a high-profile raid at a private firm in Gurugram on…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Sun Pharma Launches UNLOXCYT for Advanced Skin Cancer in US

Sun Pharma Launches UNLOXCYT for Advanced Skin Cancer in US

Unlicensed medical device stock worth Rs. 4.47 lakh seized in Gurugram raid

Unlicensed medical device stock worth Rs. 4.47 lakh seized in Gurugram raid

Controlled substances charge: Court summons Ramdev, Amazon founder

Controlled substances charge: Court summons Ramdev, Amazon founder

Allahabad HC refuses to quash case against pharma company linked to cough syrup deaths in Uzbekistan

Allahabad HC refuses to quash case against pharma company linked to cough syrup deaths in Uzbekistan

IPC registers 44 small-scale medtech firms under ADRMS

IPC registers 44 small-scale medtech firms under ADRMS

Over 9,000 deaths due to respiratory diseases in Delhi

Over 9,000 deaths due to respiratory diseases in Delhi